Schneider E, Rolli-Derkinderen M, Arock M, Dy M (2002) Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 24: 255-263.
Dy M, Schneider E (2004) Histamine-cytokine connection in immunity and hematopoiesis. Cytokine & Growth Factor Reviews 15: 393-410.
Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA (2002) Immune regulation by histamine. Curr Opin Immunol 14: 735-740.
Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59: 415-419.
Schneider E, Machavoine F, Pléau JM, Bertron AF, Thurmond RL, et al. (2005) Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels. J Exp Med 202: 387-393.
Labella FS, Brandes LJ (2000) Interaction of histamine and other bioamines with cytochromes P450: implications for cell growth modulation and chemopotentiation by drugs. Sem Cancer Biol 10: 47-1053.
Jutel MT, Watanabe T, Klunker S, Akdis M, Thomet OA, et al. (2001) Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 413: 420-424.
Miyoshi AK, Horio KS, Fukui H (2006) Recent advances in molecular pharmacology of the histamine systems: regulation of histamine H1 receptor signalling by changing its expression level. J Pharmacol Sci 101: 3-6.
Liu C, Wilson SJ, Kuei C, Lovenberg TW (2001) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 59: 420-6.
Buckland KF, Williams TJ, Conroy DM (2003) Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br J Pharmacol 140: 1117-1127.
Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, et al. (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule up-regulation. Brit J Pharmacol 142: 161-171.
Takeshita K, Sakai K, Bacon KB, Gantner F (2003) Critical role of histamine H4 receptor in leukotriene B4 production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. J Pharmacol Exp Ther 307: 1072-1080.
Gutzmer R, Diestel C, Mommert S, Köther B, Stark H, et al. (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 174: 5224-5232.
Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, et al. (2002) Histamine H4 and H2 receptors control histamine-induced interleukin-16 release from human CD8+ T cells. J Pharmacol Exp Ther 303: 300-307.
Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, et al. (2006) The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 176: 7062-70.
de Esch IJ, Thurmond RL, Jongejan A, Leurs R (2005) The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26: 462-9.
Byron JW (1977) Mechanism for histamine H2-receptor induced cell-cycle changes in the bone marrow stem cell. Agents and Actions 7: 209-213.
Schneider E, Piquet-Pellorce C, Dy M (1990) New role for histamine in interleukin-3 induced proliferation of hematopoietic stem cells. J Cell Physiol 143: 337-343.
Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, et al. (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309: 404-413.
Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, et al. (2004) Mouse development and cell proliferation in the absence of D-cyclins. Cell 118: 477-91.
Stork JS, Schmitt JM (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trend in Cell Biology 12: 258-266.
Cheng JC, Kinjo K, Judelson DR, Chang J, Wu WS, et al. (2008) CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 1: 11182-1192.
Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, et al. (2005) The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 11: 6807-6815.
Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jiménez F, et al. (2008) The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 7: 28-35.
Steinman RA (2002) Cell cycle regulators and hematopoiesis. Oncogene 21: 3403-13.
Cheng T, Rodrigues N, Dombrowski D, Stier S, Scadden DT (2000) Stem cell repopulation efficiency but not pool size is governed by p27kip1. Nature Med 6: 1235-1240.
Coats S, Whyte P, Fero ML, Lacy S, Chung G, Randel E, Firpo E, Roberts JM (1999) A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells. Curr Biol 25: 163-73.
Botnick L, Hannon E, Viognuelle R, Hellman S (1981) Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res 41: 2338-2342.
Mulder PO, Sleijfer DT, Willemse PH, de Vries EG, Uges DR, Mulder NH (1989) High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49: 4654-4658.
Gabrilove JL (2001) Cancer therapy: New strategies and treatment modalities for optimizing patient outcome. Sem Hematol 38: 1-7.
Moore MA (1991) Clinical implications of positive and negative hematopoietic stem cell regulators. Blood 78: 1-19.
Hornung RL, Longo DL (1992) Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80: 77-83.
Nagler A, Korenstein-Ilan A, Amiel A, Avivi L (2004) Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 32: 122-130.
Phillips KA, Tannok F (1998) Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 16: 3179-190.
Massé A, Ramirez LH, Bindoula G, Grillon C, Wdzieczak-Bakala J, et al. (1998) The tetrapeptide Acetyl-N-Ser-Asp-Lys Pro (Goralatide) protects mice from doxorubicin-induced toxicity: an improvement in both survival and hematological protection for early marrow stem cells and progenitors. Blood 91: 441-449.
Santini V (2001) Amifostine: chemotherapeutic and radiotherapeutic protective effects. Expert Opin Pharmacother 2: 479-489.
Guest I, Uetrecht J (2001) Bone marrow stem cell protection from chemotherapy by low-molecular-weight compounds. Exp Hematol 29: 123-137.
Broxmeyer HE, Pelus LM, Kim CH, Cooper S, Hromas R (2006) Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C. Exp Hematol 34: 1069-1077.
Rivera ES, Cricco GP, Engel NI, Fitzsimons CP, Martín GA, et al. (2000) Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Semin Cancer Biol 10: 15-23.
Medina V, Cricco GP, Nuñez M, Martín GA, Mohamad N, et al. (2006) Histamine-mediated signaling process in human malignant mammary cells. Cancer Biology & Therapy 5: 1462-1471.
Boer K, Helinger E, Helinger A, Pocza P, Pos Z, et al. (2008) Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumors by histamine. Eur J Cell Biol 87: 227-236.
Bertolini F, Battaglia M, Lanza A, Gibelli N, Palermo B, et al. (1997) Multilineage long-term engraftment potential of drug-resistant hematopoietic progenitors. Blood 90: 3027-3036.
